Organogenesis (ORGO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ORGO Organogenesis

Watchlist

3.540
-0.120-3.28%

Trading Dec 12 15:12 ET

469.32MMarket Cap-70.80P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Insider Sale: President and CEO of $ORGO (ORGO) Sells 18,416 Shares
Quiver QuantitativeDec 9 20:16 ET
Morgan Stanley Initiates Organogenesis(ORGO.US) With Hold Rating, Announces Target Price $4
Moomoo NewsDec 2 08:31 ET · Ratings
Organogenesis Assumed With an Equal Weight at Morgan Stanley
TipRanksDec 2 08:10 ET
Organogenesis Announces Plans To Expand Manufacturing Capacity With A Long-Term Lease A Biomanufacturing Facility Located At 100 Technology Way In Smithfield, Rhode Island
BenzingaNov 22 16:09 ET
US Manufacturing Index Rises To 43, Highest Since 2020
Business TodayNov 16 02:13 ET
Organogenesis Holdings Inc. Applauds CMS Decision on Coverage for Skin Substitute Products for Diabetic and Venous Ulcers
Quiver QuantitativeNov 15 09:30 ET

Comments

Jaguar8

Nov 22 15:06

NEWS

$Organogenesis (ORGO.US)$
Organogenesis Expands Manufacturing Capacity to Support Future Growth
Organogenesis Holdings (Nasdaq: ORGO) announced plans to expand its manufacturing capacity through a long-term lease of a 122,000-square foot state-of-the-art biomanufacturing facility in Smithfield, Rhode Island. The regenerative medicine company, which focuses on Advanced Wound Care and Surgical and Sports Medicine markets, will maintain its existing operations across multiple locations includi...

Jaguar8

Nov 12 15:03

NEWS

$Organogenesis (ORGO.US)$
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

Jaguar8

Nov 11 16:05

NEWS

$Organogenesis (ORGO.US)$
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
Organogenesis Holdings (ORGO) announced positive interim analysis results from its second Phase 3 clinical trial of ReNu for knee osteoarthritis treatment. The analysis, covering 50% of 474 planned patients with moderate to severe knee OA, focused on the 6-month primary endpoint. The independent Data Monitoring Committee recommended proceeding without modi...

Jaguar8

Oct 1 15:08

NEWS

$Organogenesis (ORGO.US)$
Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
• Robust 218-patient RCT demonstrates statistically superior frequency of wound closure at 12 weeks compared to standard of care (p=.04)
• Organogenesis believes published study satisfies requirements for Medicare coverage under proposed Local Coverage Determination (LCDs)
CANTON, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) ...

TrendTrader

May 10 13:52

Over 3.2 can see 3.5 and 3.75-3.8

$Organogenesis (ORGO.US)$

Heat List

Overall

No Data